Pulmonary embolism in COVID-19 pneumonia patients admitted to temporary hospital - The follow-up study.


Journal

Advances in medical sciences
ISSN: 1898-4002
Titre abrégé: Adv Med Sci
Pays: Netherlands
ID NLM: 101276222

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 17 04 2023
revised: 04 07 2023
accepted: 18 08 2023
medline: 24 11 2023
pubmed: 27 8 2023
entrez: 26 8 2023
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is linked with major coagulation disorders, especially higher risk of developing pulmonary embolism (PE). Our study summarizes COVID-19 patients' management with concomitant PE during the first weeks of pandemic and underlines the importance of D-dimer concentration assessment at admission in terms of prognosis. Study group consisted of 107 outpatients (mean age 68.91 ​± ​12.83 years) admitted to the Temporary COVID-19 Hospital in Bialystok, Poland with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and suspicion of PE based on elevated D-dimer concentration (>500 ​μg/l) and/or low saturation rate (<90%). The clinical follow-up lasted 6 months. Death or re-hospitalization were used as composite clinical endpoint (CEP). Cumulative incidence of PE was 62.3% (73/107 patients). Most of the patients were in the intermediate PE risk group according to the pulmonary embolism severity index (PESI) score. The mean total computed tomography (CT) lung involvement of COVID-19 findings was 48.42 ​± ​27.71%. Neither D-dimers nor NT-proBNP concentrations correlated significantly with the percentage of lung abnormalities in CT. Patients with baseline D-dimer concentration higher than 1429 ​μg/l had worse prognosis in 6-months observation, log-rank test, p ​= ​0.009. Ongoing SARS-CoV-2 infection along with massive involvement of lung tissue and concomitant thrombi in pulmonary arteries are challenging for physicians. It seems that simple D-dimer concentration assessment at admission may be a helpful tool not only to predict PE but also to estimate the long-term prognosis.

Identifiants

pubmed: 37633116
pii: S1896-1126(23)00026-3
doi: 10.1016/j.advms.2023.08.002
pii:
doi:

Substances chimiques

Fibrin Fibrinogen Degradation Products 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

270-275

Informations de copyright

Copyright © 2023 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interests.

Auteurs

Tomasz Lewczuk (T)

Department of Cardiology, Medical University of Bialystok, Bialystok, Poland.

Remigiusz Kazimierczyk (R)

Department of Cardiology, Medical University of Bialystok, Bialystok, Poland.

Bozena Sobkowicz (B)

Department of Cardiology, Medical University of Bialystok, Bialystok, Poland.

Anna Lisowska (A)

Department of Cardiology, Medical University of Bialystok, Bialystok, Poland. Electronic address: anlila@poczta.onet.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH